OBJECTIVES: To describe a severe form of demyelinating HIV-associated leukoencephalopathy in AIDS patients failing highly active antiretroviral therapy (HAART), its relationship to clinical and neuroimaging findings, and suggest hypotheses regarding pathogenesis. DESIGN AND METHODS: AIDS patients who failed HAART and displayed severe leukoencephalopathy were included. All cases had detailed neuromedical, neuropsychological, neuroimaging and postmortem neuropathological examination. Immunocytochemical and PCR analyses were performed to determine brain HIV levels and to exclude other viruses. RESULTS: Seven recent autopsy cases of leukoencephalopathy in antiretroviral-experienced patients with AIDS were identified. Clinically, all were severely immunosuppressed, six (86%) had poorly controlled HIV replication despite combination antiretroviral therapy, and five (71%) had HIV-associated dementia. Neuropathologically, all seven had intense perivascular infiltration by HIV-gp41 immunoreactive monocytes/macrophages and lymphocytes, widespread myelin loss, axonal injury, microgliosis and astrogliosis. The extent of damage exceeds that described prior to the use of HAART. Brain tissue demonstrated high levels of HIV RNA but evidence of other pathogens, such as JC virus, Epstein-Barr virus, cytomegalovirus, human herpes virus type-8, and herpes simplex virus types 1 and 2, was absent. Comparison of the stages of pathology suggests a temporal sequence of events. In this model, white matter damage begins with perivascular infiltration by HIV-infected monocytes, which may occur as a consequence of antiretroviral-associated immune restoration. Intense infiltration by immune cells injures brain endothelial cells and is followed by myelin loss, axonal damage, and finally, astrogliosis. CONCLUSIONS: Taken together, our findings provide evidence for the emergence of a severe form of HIV-associated leukoencephalopathy. This condition warrants further study and increased vigilance among those who provide care for HIV-infected individuals.
OBJECTIVES: To describe a severe form of demyelinating HIV-associated leukoencephalopathy in AIDSpatients failing highly active antiretroviral therapy (HAART), its relationship to clinical and neuroimaging findings, and suggest hypotheses regarding pathogenesis. DESIGN AND METHODS: AIDSpatients who failed HAART and displayed severe leukoencephalopathy were included. All cases had detailed neuromedical, neuropsychological, neuroimaging and postmortem neuropathological examination. Immunocytochemical and PCR analyses were performed to determine brain HIV levels and to exclude other viruses. RESULTS: Seven recent autopsy cases of leukoencephalopathy in antiretroviral-experienced patients with AIDS were identified. Clinically, all were severely immunosuppressed, six (86%) had poorly controlled HIV replication despite combination antiretroviral therapy, and five (71%) had HIV-associated dementia. Neuropathologically, all seven had intense perivascular infiltration by HIV-gp41 immunoreactive monocytes/macrophages and lymphocytes, widespread myelin loss, axonal injury, microgliosis and astrogliosis. The extent of damage exceeds that described prior to the use of HAART. Brain tissue demonstrated high levels of HIV RNA but evidence of other pathogens, such as JC virus, Epstein-Barr virus, cytomegalovirus, human herpes virus type-8, and herpes simplex virus types 1 and 2, was absent. Comparison of the stages of pathology suggests a temporal sequence of events. In this model, white matter damage begins with perivascular infiltration by HIV-infected monocytes, which may occur as a consequence of antiretroviral-associated immune restoration. Intense infiltration by immune cells injures brain endothelial cells and is followed by myelin loss, axonal damage, and finally, astrogliosis. CONCLUSIONS: Taken together, our findings provide evidence for the emergence of a severe form of HIV-associated leukoencephalopathy. This condition warrants further study and increased vigilance among those who provide care for HIV-infected individuals.
Authors: R F Miller; S B Lucas; M A Hall-Craggs; N S Brink; F Scaravilli; R J Chinn; B E Kendall; I G Williams; M J Harrison Journal: J Neurol Neurosurg Psychiatry Date: 1997-04 Impact factor: 10.154
Authors: R K Heaton; R A Velin; J A McCutchan; S J Gulevich; J H Atkinson; M R Wallace; H P Godfrey; D A Kirson; I Grant Journal: Psychosom Med Date: 1994 Jan-Feb Impact factor: 4.312
Authors: E H Aylward; P D Brettschneider; J C McArthur; G J Harris; T E Schlaepfer; J D Henderer; P E Barta; A Y Tien; G D Pearlson Journal: Am J Psychiatry Date: 1995-07 Impact factor: 18.112
Authors: Justin C McArthur; Norman Haughey; Suzanne Gartner; Kathy Conant; Carlos Pardo; Avi Nath; Ned Sacktor Journal: J Neurovirol Date: 2003-04 Impact factor: 2.643
Authors: C Zucchella; E Sinforiani; E Tavazzi; S Del Bue; S Novati; R Maserati; M Ceroni; S Bastianello; L Minoli; P Ferrante; E Marchioni Journal: Neurol Sci Date: 2011-06-01 Impact factor: 3.307
Authors: Dianne Langford; Jennifer Marquie-Beck; Sergio de Almeida; Deborah Lazzaretto; Scott Letendre; Igor Grant; J Allen McCutchan; Eliezer Masliah; Ronald J Ellis Journal: J Neurovirol Date: 2006-04 Impact factor: 2.643
Authors: Ann Rearden; Rosemary Hurford; Nhan Luu; Emily Kieu; Melissa Sandoval; Georgina Perez-Liz; Luis Del Valle; Henry Powell; T Dianne Langford Journal: J Neurosci Res Date: 2008-08-15 Impact factor: 4.164